早期气管内布地奈德减少极早产儿支气管肺发育不良:布地奈德在婴儿中(BiB)随机临床试验
这项双盲随机临床试验在美国新生儿研究网络17个中心开展,纳入641名22至28周胎龄或401至1000克出生体重的极早产儿,比较布地奈德(0.25 mg/kg)联合肺表面活性物质与单用肺表面活性物质的效果。结果显示,布地奈德联合肺表面活性物质组与单用肺表面活性物质组的生理性支气管肺发育不良或死亡发生率分别为68.5%和67.9%(校正RR 1.00,95%CI 0.90-1.11),联合组高血糖发生率更高(66.7% vs 49.8%;校正RR 1.33,95%CI 1.17-1.51)。
要点
- 布地奈德联合肺表面活性物质未降低极早产儿36周矫正胎龄时支气管肺发育不良或死亡风险(校正RR 1.00,95%CI 0.90-1.11)。
- 布地奈德联合肺表面活性物质组高血糖发生率高于单用肺表面活性物质组(66.7% vs 49.8%;校正RR 1.33,95%CI 1.17-1.51)。
- 试验因中期分析达到预设无效阈值而提前终止,实际入组641名(占计划1160名的55.3%)。
核心结论
- 在这项大型多中心试验中,布地奈德联合肺表面活性物质与单用肺表面活性物质相比,未降低极早产儿36周矫正胎龄时支气管肺发育不良或死亡的风险。
研究设计与样本
- 双盲随机临床试验,2021年4月至2024年6月在美国新生儿研究网络17个中心开展。
- 纳入22至28周胎龄或401至1000克出生体重、临床决定给予肺表面活性物质的婴儿,既往使用肺表面活性物质为排除标准。
- 婴儿按1:1随机分配接受1至2剂布地奈德(0.25 mg/kg)联合肺表面活性物质(poractant alfa)或单用肺表面活性物质,出生后50小时内经气管内给药。
- 实际入组641名婴儿(占计划1160名的55.3%),平均出生体重810克(SD 256克),平均胎龄25.9周(SD 1.9周)。
- 试验因50%入组时中期分析达到预设无效阈值而提前终止。
主要发现
- 布地奈德联合肺表面活性物质组支气管肺发育不良或死亡发生率为68.5%,单用肺表面活性物质组为67.9%(校正RR 1.00,95%CI 0.90-1.11)。
- 布地奈德联合肺表面活性物质组死亡率为15.3%,单用肺表面活性物质组为13.2%(校正RR 1.13,95%CI 0.78-1.64)。
- 存活至36周矫正胎龄的婴儿中,布地奈德联合肺表面活性物质组支气管肺发育不良发生率为62.9%,单用肺表面活性物质组为63.0%(校正RR 0.99,95%CI 0.87-1.12)。
- 布地奈德联合肺表面活性物质组高血糖发生率高于单用肺表面活性物质组(66.7% vs 49.8%;校正RR 1.33,95%CI 1.17-1.51)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因50%入组时中期分析达到预设无效阈值而提前终止,实际入组641名(占计划1160名的55.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Extremely preterm infants are at high risk for bronchopulmonary dysplasia (BPD) and death. Multiple small randomized clinical trials showed that a combination of budesonide with surfactant compared with surfactant alone reduced BPD or death. OBJECTIVE: To determine if early intratracheal administration of a combination of budesonide (0.25 mg/kg) mixed with surfactant, compared with surfactant alone, reduces physiologic BPD or death by 36 weeks' postmenstrual age in extremely preterm infants. DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized clinical trial was conducted from April 2021 to June 2024 in the 17 centers of the United States Neonatal Research Network. Infants 22 to 28 weeks' gestation or 401 to 1000 g birth weight were enrolled after clinical decision to give surfactant, with the first dose of surfactant being study drug (prior surfactant was an exclusion criterion). INTERVENTIONS: Infants were randomly allocated 1:1 to receive 1 to 2 doses of budesonide + surfactant (poractant alfa) or surfactant alone via endotracheal tube within 50 hours of birth. MAIN OUTCOMES AND MEASURES: The primary outcome was physiologic BPD or death by 36 weeks' postmenstrual age. There were 5 prespecified secondary outcomes and multiple prespecified exploratory and safety outcomes. RESULTS: The trial was stopped with 641 infants enrolled (55.3% of 1160 planned; mean birth weight, 810 g [SD, 256 g]; gestational age, 25.9 weeks [SD, 1.9 weeks]), because interim analysis at 50% enrollment reached the prespecified futility threshold. The incidence of BPD or death was 68.5% in the budesonide + surfactant group and 67.9% in the surfactant-alone group (adjusted relative risk [RR], 1.00 [95% CI, 0.90-1.11]). No differences were noted in mortality (15.3% vs 13.2%; adjusted RR, 1.13 [95% CI, 0.78-1.64]) or BPD among survivors to 36 weeks' postmenstrual age (62.9% vs 63.0%; adjusted RR, 0.99 [95% CI, 0.87-1.12]). More infants who received budesonide + surfactant compared with surfactant alone had hyperglycemia (66.7% vs 49.8%; adjusted RR, 1.33 [95% CI, 1.17-1.51]). CONCLUSIONS AND RELEVANCE: In this large multicenter trial, the combination of budesonide with surfactant did not reduce the risk of BPD or death at 36 weeks' postmenstrual age in extremely preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04545866.
引用
- Ambalavanan N, Carlo WA, Nowak KJ, et al. Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial. JAMA. 2025. PMID: 41026481. doi:10.1001/jama.2025.16450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。